Watertown, Mass.-based Enanta Pharmaceuticals and North Chicago, Ill.-based Abbvie are collaborating to develop the drugs, called glecaprevir and pibrentasvir.
The FDA’s breakthrough therapy designation program is intended to accelerate the development and review of an experimental treatment for a serious or life threatening condition when early clinical evidence shows potential for substantial improvement over existing treatment methods.
More articles on supply chain:
Delivery drones decade away from federal approval: 3 things to know
Blood separation technology wins FDA approval
Why EpiPens are so much cheaper in Europe
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
